DrugPatentWatch Database Preview
Litigation Details for CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2018)
» See Plans and Pricing
CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2018)
| Docket | Start Trial | Date Filed | 2018-03-15 |
| Court | District Court, D. New Jersey | Date Terminated | |
| Cause | 15:1126 Patent Infringement | Assigned To | Susan Davis Wigenton |
| Jury Demand | None | Referred To | Leda Dunn Wettre |
| Patents | 8,921,348; 9,829,495; 9,943,526 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC.
The small molecule drug covered by the patents cited in this case is Start Trial .
Details for CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-07-06 | 15 | Amended Complaint | of United States Patent Nos. 8,921,348 (“’348 patent”), 9,829,495 (“’495 patent”), and 9,943,526 … States Patent (10) Patent No.: US 8,921,348 B2 … 300 mg, before the expiration of U.S. Patent Nos. 8,921,348 and 9,829,495....” 44. … 300 mg, before the expiration of U.S. Patent Nos. 8,921,348 and 9,829,495....” 52. … US 8,921,348 B2 1 | External link to document |
| 2020-06-23 | 152 | Opinion | regarding patent claims in Plaintiff’s U.S. Patent Nos. 8,921,348 (“the ʼ348 Patent”) and 9,829,495 (“the … The ’348 Patent and ’495 Patent, along with U.S. Patent No. 10,195,214 (“the ’214 Patent”), are collectively…regarding their request for patent claim construction pursuant to Local Patent Rule 4.5(a). This Court has…treatment by mifepristone.” (’348 Patent at Abstract.) 7 According to the patent, “administration of the same…produce excess cortisol. (’495 Patent at 1:23–24, 2:24– 29.) The ’495 Patent discloses a method to differentially | External link to document |
| 2018-10-23 | 31 | Opinion | the holder of patent numbers 8,921,348 (the “’348 patent”), 9,829,495 (the “’495 patent”) and 9,943,526…9,943,526 (the “’526 patent”) (collectively, the “patents-in-suit”) and listed those patents in the Orange …process, applicants file “the patent number and the expiration date of any patent which claims the drug for…ANDAs must address patents that cover or might cover the relevant drugs. For each patent, companies can …Ex. A, B, C.) 1 The ‘348 patent was issued by the United States Patent and Trademark Office (“USPTO | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
